Bayer (XTRA:BAYN) Stock May Still Offer Value Despite NUBEQA Trial News

What happened: Bayer shares have drawn valuation attention after a strong run, with coverage weighing whether the price is supported by sales across its pharmaceutical and crop science operations, alongside NUBEQA trial news and the VERQUVO Canada deal. Key numbers: Stock up 105.8% over the past year. Why it matters: The article says the current 1.2x screens as undervalued on a tailored P/S yardstick, and notes Bayer recently raised its 2026 profit forecast on a pharma recovery. Community views split between execution upside and legal and balance sheet strain. Market: +3.8% today ($43.82), -13.6% YTD, 1.1x vol — as of 16:04 UTC

Bayer shares have drawn valuation attention after a strong run, with coverage weighing whether the price is supported by sales across its pharmaceutical and crop science operations, alongside NUBEQA trial news and the VERQUVO Canada deal.

The article says the current 1.2x screens as undervalued on a tailored P/S yardstick, and notes Bayer recently raised its 2026 profit forecast on a pharma recovery. Community views split between execution upside and legal and balance sheet strain. Market: +3.8% today ($43.82), -13.6% YTD, 1.1x vol — as of 16:04 UTC